NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jul 03 04:00PM ET
2.87
Dollar change
0.00
Percentage change
0.00
%
Index- P/E- EPS (ttm)-0.31 Insider Own16.55% Shs Outstand159.00M Perf Week2.50%
Market Cap456.33M Forward P/E- EPS next Y-0.04 Insider Trans0.00% Shs Float132.68M Perf Month8.30%
Enterprise Value394.60M PEG- EPS next Q-0.01 Inst Own61.06% Short Float6.00% Perf Quarter21.10%
Income-47.34M P/S- EPS this Y58.86% Inst Trans6.84% Short Ratio5.70 Perf Half Y-18.47%
Sales0.00M P/B7.60 EPS next Y-68.78% ROA-76.20% Short Interest7.96M Perf YTD-18.00%
Book/sh0.38 P/C7.30 EPS next 5Y25.31% ROE-92.00% 52W High5.02 -42.83% Perf Year-20.94%
Cash/sh0.39 P/FCF- EPS past 3/5Y- 34.82% ROIC-78.79% 52W Low1.58 82.22% Perf 3Y90.07%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility6.36% 6.01% Perf 5Y-7.42%
Dividend TTM- EV/Sales- EPS Y/Y TTM-24.80% Oper. Margin- ATR (14)0.16 Perf 10Y-
Dividend Ex-Date- Quick Ratio8.92 Sales Y/Y TTM- Profit Margin- RSI (14)61.43 Recom1.11
Dividend Gr. 3/5Y- - Current Ratio8.92 EPS Q/Q-29.11% SMA204.57% Beta0.44 Target Price7.44
Payout- Debt/Eq0.01 Sales Q/Q- SMA5013.03% Rel Volume0.57 Prev Close2.87
Employees36 LT Debt/Eq0.00 EarningsMay 13 BMO SMA200-8.16% Avg Volume1.40M Price2.87
IPOApr 24, 2019 Option/ShortYes / Yes EPS/Sales Surpr.-181.69% -100.00% Trades Volume799,203 Change0.00%
Date Action Analyst Rating Change Price Target Change
Mar-27-25Initiated JP Morgan Overweight $7
Dec-06-24Initiated Jefferies Buy $7
Jun-13-24Initiated Robert W. Baird Outperform $8
Oct-13-23Resumed BTIG Research Buy $4
Aug-12-22Initiated Cantor Fitzgerald Overweight $4
May-05-21Initiated BTIG Research Buy $10
Apr-05-21Initiated Needham Buy $10
May-13-25 07:30AM
Apr-16-25 03:00PM
11:23AM
Mar-26-25 07:30AM
Mar-20-25 12:00PM
07:30AM Loading…
Mar-05-25 07:30AM
Feb-11-25 11:00AM
Feb-10-25 02:12PM
Jan-12-25 11:05AM
Jan-07-25 07:30AM
Dec-30-24 02:50PM
Dec-07-24 05:20AM
Dec-06-24 01:18PM
Nov-14-24 07:30AM
Nov-12-24 07:30AM
09:06AM Loading…
Oct-16-24 09:06AM
Sep-18-24 08:21AM
Sep-12-24 05:35PM
Aug-13-24 08:00AM
Jun-15-24 11:42PM
Jun-14-24 07:50AM
Jun-12-24 07:45AM
Jun-11-24 05:47PM
May-30-24 07:30AM
May-15-24 04:01PM
Apr-12-24 09:35AM
Apr-03-24 07:30AM
Mar-27-24 05:27PM
04:01PM
Mar-05-24 07:30AM
03:57AM Loading…
Feb-16-24 03:57AM
Jan-08-24 07:00AM
Dec-19-23 11:21AM
Nov-03-23 11:43AM
Oct-23-23 04:01PM
Oct-14-23 04:30PM
Oct-09-23 08:00AM
Sep-21-23 07:00AM
Sep-07-23 07:30AM
Aug-10-23 11:04PM
Aug-04-23 08:12AM
Jul-07-23 07:46AM
Jul-06-23 08:00AM
May-31-23 07:00AM
May-23-23 01:43PM
May-08-23 12:46PM
May-05-23 04:06PM
Apr-21-23 12:00PM
Apr-13-23 08:00AM
Mar-28-23 04:30PM
Mar-21-23 06:30AM
Feb-08-23 07:00AM
Jan-10-23 05:35AM
Nov-15-22 09:35AM
Nov-08-22 07:00AM
Nov-02-22 04:01PM
Oct-28-22 07:00AM
Oct-24-22 04:30PM
Oct-21-22 07:00AM
Oct-18-22 11:58AM
07:00AM
Oct-17-22 07:00AM
Oct-03-22 05:00PM
09:00AM
Sep-28-22 09:21AM
Sep-26-22 07:00AM
Sep-14-22 09:00AM
Sep-12-22 08:00AM
Sep-09-22 08:22PM
Aug-31-22 07:00AM
Aug-22-22 04:00AM
Jul-05-22 04:01PM
Jun-21-22 08:30AM
Jun-20-22 10:36AM
Jun-17-22 05:30PM
03:53PM
10:21AM
03:44AM
Jun-02-22 08:00AM
May-26-22 05:05PM
04:30PM
May-17-22 08:00AM
May-09-22 07:45AM
07:00AM
May-06-22 05:12PM
05:12PM
Apr-22-22 09:35AM
Apr-06-22 08:00AM
Mar-31-22 04:01PM
Mar-03-22 08:30AM
Mar-01-22 08:00AM
Feb-10-22 08:00AM
Jan-12-22 01:59PM
Dec-29-21 01:19AM
Dec-22-21 07:00AM
Dec-17-21 12:38AM
Dec-15-21 09:38PM
Dec-13-21 07:00AM
Dec-10-21 09:38PM
Nov-30-21 07:00AM
Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its portfolio include Etigilimab (MPH-313), Alvelestat (MPH-966), Setrusumab (BPS-804), Navicixizumab (OMP-305B83), Acumapimod (BCT-197), and Leflutrozole (BGS-649). The company was founded by Denise Vera Scots-Knight, Charles Edward Sermon, Alastair Graham MacKinnon, and John P. Richard in March 10, 2015 and is headquartered in London, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Scots-Knight DeniseChief Executive OfficerSep 13 '24Sale4.2260,046253,454808,921Sep 16 08:50 PM
Scots-Knight DeniseChief Executive OfficerSep 12 '24Sale4.4728,611127,968868,967Sep 16 08:50 PM
Lewicki John A.Chief Scientific OfficerSep 13 '24Sale4.2210,93746,16578,630Sep 16 08:49 PM
Lewicki John A.Chief Scientific OfficerSep 12 '24Sale4.475,21223,31289,567Sep 16 08:49 PM
Sermon CharlesGeneral CounselSep 13 '24Sale4.2220,94688,413219,061Sep 16 08:48 PM
Sermon CharlesGeneral CounselSep 12 '24Sale4.479,98044,638240,007Sep 16 08:48 PM
Fox Christine AnnChief Financial OfficerSep 13 '24Sale4.2219,15880,86689,285Sep 16 08:47 PM
Fox Christine AnnChief Financial OfficerSep 12 '24Sale4.479,12840,827108,443Sep 16 08:47 PM
Hughes-Wilson AlexandraSee RemarksSep 13 '24Sale4.22100,312423,41750,475Sep 16 08:46 PM
Hughes-Wilson AlexandraSee RemarksSep 12 '24Sale4.4747,798213,786150,787Sep 16 08:46 PM
Sermon CharlesGeneral CounselSep 11 '24Option Exercise0.0065,6000249,987Sep 13 04:57 PM
Fox Christine AnnChief Financial OfficerSep 11 '24Option Exercise0.0060,0000117,571Sep 13 04:50 PM
Lewicki John A.Chief Scientific OfficerSep 11 '24Option Exercise0.0046,000094,779Sep 13 04:49 PM
Scots-Knight DeniseChief Executive OfficerSep 11 '24Option Exercise0.00188,0600897,578Sep 13 04:49 PM
Hughes-Wilson AlexandraSee RemarksSep 11 '24Option Exercise0.99208,333206,416242,881Sep 13 04:47 PM
Alexandra Hughes-WilsonOfficerSep 12 '24Proposed Sale4.66148,110690,193Sep 12 04:05 PM
Scots-Knight DeniseOfficerSep 12 '24Proposed Sale4.6688,657413,142Sep 12 04:05 PM
Sermon CharlesOfficerSep 12 '24Proposed Sale4.6630,926144,115Sep 12 04:05 PM
Lewicki John A.OfficerSep 12 '24Proposed Sale4.6616,14975,254Sep 12 04:05 PM
Fox Christine AnnOfficerSep 12 '24Proposed Sale4.6628,286131,813Sep 12 04:05 PM
PAKIANATHAN DEEPIKADirectorAug 22 '24Option Exercise1.44105,244151,116105,244Aug 23 06:13 PM
PAKIANATHAN DEEPIKADirectorAug 22 '24Sale4.43105,244466,2100Aug 23 06:13 PM
Deepika PakianathanDirectorAug 22 '24Proposed Sale4.43105,244466,210Aug 22 06:35 PM